Pacific Edge reviews US pricing for new Cxbladder test, trading halted

Pacific Edge reviews US pricing for new Cxbladder test, trading halted
Pacific Edge says Cxbladder Triage Plus delivers “significant performance improvements” compared to its existing tests. (Image: Pacific Edge)
Rebecca Howard
Pacific Edge has been placed on a trade halt while it reviews draft gapfill or reimbursement rates for its new Cxbladder Triage Plus test from the US Centres for Medicare and Medicaid Services.“[It said it's] reviewing the prices and the associated documentation and needs time to assess the implications of them, consult with its advisers and industry partners, and prepare an announcement that provides context to investors.”Gapfill prices are proposed reimbursement rates for new or unpriced clinical diagnostic laboratory tests.Th...

More Markets

SkyCity’s $330m Fletcher claim faces ‘high bar’
Markets

SkyCity’s $330m Fletcher claim faces ‘high bar’

Analysts believe the casino operator’s NZICC claim is unlikely to succeed.

Fonterra's consumer business likely to be sold as one
Primary Sector

Fonterra's consumer business likely to be sold as one

That figure feels expensive to one analyst on this side of the Tasman.

NZ business brokers report sales rise
Markets

NZ business brokers report sales rise

A generation of business owners are starting to get "exit ready", Link says.